

Stereoselective Construction of the C²¹–C⁴² Fragment of Rapamycin

K. C. Nicolaou,* P. Bertinato, A. D. Piscopio, T. K. Chakraborty and N. Minowa

Department of Chemistry, University of California, San Diego, 9500 Gilman Drive, La Jolla, California 92093, USA

Department of Chemistry, The Scripps Research Institute, 10666 North Torrey Pines Road, La Jolla, California 92037, USA

A stereoselective construction of the C²¹–C⁴² fragment **2** of rapamycin **1** via coupling and elaboration of key intermediates **3**–**6** is described.

In the preceding communication¹ we outlined a highly convergent strategy for the total synthesis of rapamycin **1**² and a stereoselective synthesis of an appropriately functionalized C⁸–C¹⁸ fragment. In this communication we report enantioselective and efficient syntheses of the remaining three fragments C²¹–C²⁸ (**3**), C²⁹–C³⁴ (**4**) and C³⁵–C⁴² **5** and their coupling and elaboration to the advanced C²¹–C⁴² key intermediate **2** (Scheme 1).

Scheme 2 summarizes the construction of the C²¹–C²⁸ fragment **3**.[†] Thus, coupling of intermediates **7** and **8**[‡] under Evans aldol conditions³ led stereoselectively to product **9** in 85% yield. The carboximide moiety was then converted to a methyl group in 80% overall yield via a known three-step sequence. The resulting intermediate **10** was desilylated (93%) and converted to *p*-methoxybenzylidene derivative **11** in 95% yield. Finally, regioselective opening of the benzylidene acetal with DIBAL⁵ followed by Swern oxidation afforded the targeted intermediate **3**[§] in 94% overall yield.

[†] All new compounds exhibited satisfactory spectral and analytical and/or exact mass data. Yields refer to chromatographically and spectroscopically homogeneous materials.

[‡] Oxazolidinone **7** was obtained from (+)- β -citronellene by selective cleavage of the trisubstituted double bond [*m*-chloroperbenzoic acid (mCPBA), HClO₄, NaIO₄ and Jones oxidation, see: D. R. Williams, B. A. Barner, K. Nichitani and J. U. Phillips, *J. Am. Chem. Soc.*, 1982, **104**, 4708], followed by acid chloride formation and condensation with the lithio-oxazolidinone derived from (1*S*,2*R*)-norephedrine, see: D. A. Evans, *Aldrichim. Acta*, 1982, **15**, 23.

Aldehyde **8** was prepared from bis(benzylidene)mannitol by bis(methylation) (NaH–MeI) followed by removal of the benzylidene groups [Pd(OH)₂/C cat., H₂], selective silylation at the primary positions (TBDPSCI) and cleavage of the 1,2-diol system [Pb(OAc)₄].

[§] *Selected physical properties of compounds. 3*: Colourless oil; *R*_F 0.65 (silica, 30% ethyl acetate in light petroleum); [α]_D²⁰ –55.9 (c 5.3 in CHCl₃); IR (neat): $\nu_{\max}$ /cm^{–1} 2929, 1731, 1612, 1513, 1460, 1248 and 1076; ¹H NMR (500 MHz, CDCl₃): δ 9.74 (d, *J* 1.6 Hz, CHO), 7.19 (d, *J* 8.7 Hz, 2 H, aromatic), 6.83 (d, *J* 8.7 Hz, 2 H, aromatic), 5.52 (ddd, *J* 8.6, 10.2, 17.1 Hz, 1 H, CH=CH₂), 4.94 (dd, *J* 1.9, 17.1 Hz, 1 H, olefinic), 4.90 (dd, *J* 1.9, 10.2 Hz, 1 H, olefinic), 4.43 (ABq, *J*_{AB} 11.1 Hz, $\Delta\nu_{AB}$ = 14.1 Hz, 2 H, OCH₂Ar), 3.78 (s, 3 H, ArOMe), 3.67 (dd, *J* 1.6, 3.6 Hz, 1 H, 27-H), 3.50 (dd, *J* 3.6, 6.4 Hz, 1 H, 26-H), 3.45 (s, 3 H, OMe), 2.2 (m, 1 H, 23-H), 1.9 (m, 1 H, 25-H), 1.44 (m, 1 H, 24-H), 1.1 (m, 1 H, 24-H'), 0.97 (d, *J* 6.7 Hz, 3 H, Me) and 0.91 (d, *J* 6.7 Hz, 3 H, Me); HRMS (FAB): Calc. for C₁₉H₂₈O₄CS (M + Cs⁺): 453.1042, found *m/z* 453.1033.

4: Colourless oil; *R*_F 0.45 (silica, 5% ethyl acetate in light petroleum); [α]_D²⁰ 5.37 (c 1.0 in CHCl₃); IR (neat): $\nu_{\max}$ /cm^{–1} 2952, 2858, 1612, 1512, 1463, 1378, 1300, 1249, 1174, 1093, 1042 and 939 cm^{–1}; ¹H NMR (500 MHz, CDCl₃): δ 7.23 (d, *J* 8.8 Hz, 2 H, aromatic), 6.86 (d, *J* 8.8 Hz, 2 H, aromatic), 6.04 (dq, *J* 1.5 and 9.8 Hz, 1 H, 30-H), 4.44 (s, 2 H, OCH₂Ar), 3.78 (s, 3 H, ArOMe), 3.62 (m, 1 H, 32-H), 3.43 (dd, *J* 6.5 Hz, 2 H, 34-H₂), 2.45 (m, 1 H, 31-H), 2.29 [d, *J* 1.5 Hz, 3 H, CH=C(Me)I], 1.64 (m, 1 H, 33-H), 1.22 (m, 1 H, 33-H'), 0.92 (d, *J* 6.8 Hz, 3 H, Me), 0.86 (s, 9 H, Bu^t), 0.026 and 0.012 (2 $\times$ s, 6 H, SiMe); HRMS (FAB): Calc. for C₂₂H₃₇O₃SiCS (M + Cs⁺): 637.0611, found *m/z* 637.0611.

5: Colourless foam; *R*_F 0.35 (silica, 35% ether in light petroleum); [α]_D²⁰ +3.58 (c 0.87 in CHCl₃); IR (neat): $\nu_{\max}$ /cm^{–1} 2930, 2858, 1783, 1701, 1455, 1350, 1197 and 1110; ¹H NMR (500 MHz, CDCl₃): δ 7.71 (m, 4 H, aromatic), 7.37 (m, 9 H, aromatic), 7.26 (m, 2 H, aromatic), 5.63 (d, *J* 7.0 Hz, 1 H, PhCHO), 4.71 (dq, *J* 7.0 and 7.0 Hz, 1 H,

Scheme 3 outlines the synthesis of optically active intermediate **4** starting with aldehyde **12**.[¶] Asymmetric crotylboration of **12** using Brown's conditions⁶ led to the corresponding *anti*-adduct in 70% yield [$>20:1$ diastereoselectivity and $>95\%$ enantiomeric excess (e.e.) as determined by Mosher ester formation and NMR analysis]. Protection of this compound with *p*-methoxybenzyl bromide gave **13** (90%) which was converted to acetylene **14** by (i) ozonolysis–Me₂S (80%); (ii) dibromoolefin formation⁷ (90%); and (iii) treatment with BuⁿLi–MeI (98%). Finally hydrozirconation of **14**⁸ followed by iodine quench furnished compound **4**[§] in 85% yield.


Scheme 4 outlines the construction of the key intermediate **5**. Acid induced regioselective and stereospecific opening of epoxide **15**^{||} with methanol followed by silylation led to intermediate **16** in 88% overall yield. Hydrogenolysis of the benzyl ether in **16** followed by Swern oxidation gave ketone **17** which was converted to enone **18** by palladium catalysed oxidation of the corresponding silyl enol ether (88%).⁹ Stereoselective Luche reduction^{2e,10} of **18** furnished **19** (95%) which entered a stereospecific Eschenmoser–Claisen rearrangement upon heating with *N,N*-dimethylacetamide

CHN), 3.53 (ddd, *J* 4.80, 8.59 and 13.29 Hz, 1 H, 40-W), 3.32 (s, 3 H, OMe), 3.05 (ddd, *J* 4.50, 8.59, and 12.91 Hz, 1 H, 39-H), 2.88 (m, 2 H, 35-H), 2.05 (m, 1 H, CH), 1.63 (m, 1 H, CH), 1.52 (m, 4 H, CH and CH₂), 1.03 (s, 9 H, Bu^t) and 0.7 (m, 1 H, CH); HRMS (FAB): Calc. for C₃₆H₄₅NO₅SiCS (M + Cs⁺): 732.2121, found *m/z* 732.2100.

2: Colourless foam; *R*_F 0.3 (silica, 70% ether in light petroleum); [α]_D²⁰ –4.3 (c 0.3 in CHCl₃); IR (neat): $\nu_{\max}$ /cm^{–1} 2926, 2863, 1733, 1459, 1377, 1236, 1187 and 1108; ¹H NMR (500 MHz, CDCl₃): δ 7.7 (m, 4 H, aromatic), 7.35 (m, 6 H, aromatic), 6.23 (dd, *J* 9.3 and 14.3 Hz, 1 H, 22-H), 5.91 (d, *J* 14.3 Hz, 1 H, 21-H), 5.07 (d, *J* 10.6 Hz, 1 H, 30-H), 5.07 (m, 1 H, NCHC=O), 4.08 (m, 1 H, CHO), 3.56 (dt, *J* 6.2 and 9.2 Hz, 1 H, CHO), 3.53–3.40 (m, 2 H, CHO), 3.52 (s, 3 H, 27-OMe), 3.38 (m, 1 H, CHN), 3.32 (s, 3 H, 39-OMe), 3.22 (m, 2 H, CHO), 3.03 (ddd, *J* 4.3, 8.3 and 12.5 Hz, 1 H, 39-H), 2.73 (m, 1 H, CHN), 2.6 (m, 1 H, 31-H), 2.21 (m, 1 H, 23-H), 2.05–0.6 (m, 21 H, CH and CH₂), 1.74 (s, 3 H, 29-Me), 1.07–1.03 (m, 18 H, SiCHMe₂), 1.02 (s, 9 H, Bu^t), 1.0 (d, *J* 6.5 Hz, 3 H, Me), 0.95 (t, *J* 7.9 Hz, 9 H, SiCH₂Me), 0.92 (t, *J* 7.9 Hz, 9 H, SiCH₂Me), 0.90 (d, *J* 7.5 Hz, 3 H, Me), 0.84 (d, *J* 6.6 Hz, 3 H, Me), 0.77 (d, *J* 6.8 Hz, 3 H, Me), 0.59 (q, *J* 7.9 Hz, 12 H, SiCHMe) and 0.55 (m, 3 H, SiCHMe₂); ¹³C NMR (125 MHz, CDCl₃): δ 151.69, 136.46, 135.99, 135.89, 135.21, 134.36, 130.07, 129.27, 129.22, 127.31, 127.25, 86.54, 84.51, 79.38, 78.17, 76.16, 73.41, 71.54, 61.42, 57.33, 57.27, 39.87, 38.84, 38.45, 36.57, 35.70, 33.67, 33.15, 32.87, 32.32, 30.49, 29.70, 26.98, 26.95, 21.32, 19.34, 18.42, 18.29, 17.64, 14.71, 13.21, 12.39, 12.35, 7.24, 7.11, 5.61, 5.57 and 5.23; HRMS (FAB): Calc. for C₇₂H₁₂₈NO₈Si₄ICs (M + Cs⁺): 1506.6818, found *m/z* 1506.6879.

[¶] Aldehyde **12** was prepared from but-3-ene-1-ol by silylation followed by ozonolysis.

^{||} Epoxide **15** was prepared from 2-bromocyclohexenone by asymmetric reduction (96% e.e., see: E. J. Corey and J. O. Link, *Tetrahedron Lett.*, 1989, **30**, 6275; T. K. Jones, J. J. Mohan, L. C. Xavier, T. J. Blacklock, D. J. Mathre, P. Sohar, E. T. T. Jones, R. A. Reamer, F. E. Roberts and E. J. J. Grabowski, *J. Org. Chem.*, 1991, **56**, 763) followed by reductive removal of the bromine (Li–Bu^tOH), epoxidation (mCPBA, see: H. B. Henbest and R. A. L. Wilson, *J. Chem. Soc.*, 1957, 1958) and benzylation (NaH–PhCH₂Br).



Scheme 1 Strategic bond disconnections and retrosynthetic analysis of rapamycin **1**. Definition of requisite fragments for a total synthesis.


PMB = *p*-methoxybenzyl; TES = triethylsilyl; TIPS = triisopropylsilyl; TBS = *tert*-butyldimethylsilyl; TBDPS = *tert*-butyldiphenylsilyl.

dimethyl acetal^{2e,11} to give amide **20** in 89% yield. Reduction of **20** (LiEt₃BH, 92%) followed by hydrogenation of the double bond led to alcohol **21** (96%). Conversion of **21** to the corresponding terminal olefin, followed by ozonolysis gave aldehyde **22** (72% overall yield). Finally, condensation of ketophosphonate **23**^{**} with aldehyde **22** under LiCl-PrⁱNEt¹² conditions, followed by reduction of the resulting α,β -unsaturated double bond [(i) Et₃SiH-Wilkinson's catalyst; (ii) HF-H₂O-MeCN]¹³ and resilylation (TBDPSCl) gave the key intermediate **5**[§] in 72% overall yield.

Coupling of intermediates **3**–**5** and elaboration to the desired C¹⁸–C⁴² fragment **2** was accomplished as summarized in Scheme 5. Thus, chromium–nickel¹⁴ mediated coupling of **3** and **4** led to the desired hydroxy compound **24** (87% based on 90% conversion).^{††} A silylation–selective desilylation


^{**} Ketophosphonate **23** was prepared by reacting triethyl phosphite with bromoacetylloxazolidin-2-one, see: D. A. Evans, E. B. Sjogren, A. E. Weber and R. E. Conn, *Tetrahedron Lett.*, 1987, **28**, 39.

^{††} Two (*ca.* 4:1 ratio) diastereoisomers were obtained in this step (92% yield) which were separated by standard silica gel chromatography. The minor diastereoisomer was converted back to the desired one by a two step sequence, PDC oxidation followed by Zn(BH₄)₂ reduction (ref. 2i) in 70% yield, leading to the desired product **24** in 87% overall yield.



Scheme 2 Synthesis of key intermediate **3**. *Reagents and conditions:* (a) **7** (1 equiv.), Bu₂BOTf (1.15 equiv.), Et₃N (1.3 equiv.), CH₂Cl₂ –78 to 0 °C, 1 h, then **8** (1 equiv.), –78 to 25 °C, 3 h, 85%; (b) LiBH₄ (2.2 equiv.), H₂O (2.2 equiv.), Et₂O, 0 °C, 1 h, 98%; (c) TsCl (1.2 equiv.), pyridine, 0 °C, 6 h, 90% (based on 20% recovered starting material); (d) LiEt₃BH (5 equiv.), THF, 0 to 25 °C, 12 h, 92%; (e) Bu₄NF (1.5 equiv.), THF, 0 to 25 °C, 1 h, 93%; (f) *p*-methoxybenzaldehyde dimethyl acetal (1.3 equiv.), CSA (0.2 equiv.), CH₂Cl₂, 25 °C, 4 h, 95%; (g) DIBAL (2 equiv.), CH₂Cl₂, –78 to 25 °C, 1 h, 98%; (h) (COCl)₂ (1.5 equiv.), DMSO (3.2 equiv.), Et₃N (5 equiv.), CH₂Cl₂, –78 to –10 °C, 1 h, 96%.


Tf = CF₃SO₂; Ts = *p*-MeC₆H₄SO₂; THF = tetrahydrofuran; CSA = camphorsulfonic acid; DMSO = dimethyl sulfoxide; DIBAL = diisobutylaluminium hydride.



Scheme 3 Syntheses of key intermediate **4**. *Reagents and conditions:* (a) *trans*-but-2-ene (1.3 equiv.), KOBu^t (1 equiv.) BuⁿLi (1 equiv.), (+)-Ipc₂BOMe (1.1 equiv.), BF₃·Et₂O (1.2 equiv.), THF, –78 to 25 °C, 4 h, 70%; (b) PMBBBr (1.1 equiv.), NaHMDS (1.1 equiv.), THF-DMF (2:1), 0 °C, 3 h, 90%; (c) O₃, CH₂Cl₂-MeOH-pyridine (5:5:1), –78 °C then Me₂S, –78 to 25 °C, 80%; (d) CBr₄ (2.25 equiv.), Ph₃P (2.25 equiv.), Zn (2.25 equiv.), CH₂Cl₂, 25 °C, 90%; (e) BuⁿLi (2.1 equiv.), MeI (5 equiv.), THF, –78 to 0 °C, 1 h, 98%; (f) Cp₂ZrHCl (2 equiv.), CH₂Cl₂, 25 °C, 4 h then I₂ (2 equiv.), 0 °C, 15 min., 85%.

Ipc = isopinocampheyl; NaHMDS = sodium hexamethyldisilazide; Cp = cyclopentadienyl.

sequence followed by Swern oxidation converted compound **24** to aldehyde **25** in 92% overall yield. Aldol condensation of the boron-enolate of **5** with aldehyde **25** under Evans conditions³ led stereoselectively to product **26** (95%) which was converted to compound **27** by the standard reduction–tosylation–reduction procedure (80% overall yield) as detailed in Scheme 5. Esterification of **27** with *N*-Boc-L-pipecolic acid (Boc-6) under standard carbodiimide conditions furnished the corresponding ester (85%) which was converted to *trans*-iodoolefin **28** by OsO₄ catalysed diol formation–Pb(OAc)₄ cleavage (75% overall) followed by chromium mediated iodoolefination (94%).¹⁵ Finally, exchange of the *p*-methoxybenzyl for triethylsilyl groups in **28** accompanied by



Scheme 4 Synthesis of key intermediate **5**. *Reagents and conditions:* (a) CSA (0.25 equiv.), MeOH, 25 °C, 2 h, 88%; (b) TBSOTf (1.5 equiv.), 2,6-lutidine (2 equiv.), CH₂Cl₂, 0 °C, 15 min., 98%; (c) 20% Pd(OH)₂/C, H₂, EtOH, 25 °C, 2 h, 95%; (d) (COCl)₂ (1.5 equiv.), DMSO (3.2 equiv.), Et₃N (5 equiv.), CH₂Cl₂, -78 to -10 °C, 1 h, 92% (e) LDA (1.1 equiv.), TMSCl (1.1 equiv.), THF, -78 °C, 0.5 h then Pd(OAc)₂ (1.1 equiv.), MeCN, 50 °C, 18 h, 88%; (f) LiBH₄ (4 equiv.), CeCl₃·7H₂O (2 equiv.), MeOH-THF (1:1), -78 °C, 0.5 h, 95%; (g) *N,N*-dimethylacetamide dimethyl acetal (5 equiv.), xylene, reflux, 24 h, 89%; (h) LiEt₃BH (2.2 equiv.), THF, 0 to 25 °C, 2 h, 92%; (i) 10% Pd/C, H₂, EtOH, 25 °C, 2 h, 96%; (j) *o*-NO₂C₆H₄SeCN (1.2 equiv.), Bu₃P (1.2 equiv.), THF, 0 to 25 °C, 2 h, 93%; (k) H₂O₂ (30% aq.), THF, 0 to 25 °C, 2 h, 86%; (l) O₃, CH₂Cl₂-MeOH (1:1, -78 °C, then Me₂S, -78 to 25 °C, 6 h, 92%; (m) **23** (1.5 equiv.), LiCl (1.7 equiv.), diisopropylethylamine (1.7 equiv.), MeCN, 25 °C, 4 h, 96% (n) Rh(PPh₃)₃Cl (0.05 equiv.), Et₃SiH, 50 °C, 2 h then aq. HF in MeCN (10%), 0 °C, 2.5 h followed by TBDPSCl (1.5 equiv.), imidazole (3 equiv.), DMF, 25 °C, 6 h, 75% overall.

LDA = lithium diisopropylamide; TMS = trimethylsilyl; DMF = dimethylformamide; Bn = benzyl.

concomitant removal of the Boc group furnished the targeted advanced key intermediate **28** in 92% overall yield.


The described chemistry sets the stage for the total synthesis of rapamycin **1** and designed congeners.

This work was financially supported by the National Institutes of Health, the University of California, San Diego and The Scripps Research Institute. A. D. P. is the recipient of an NIH Fellowship, 1990–1992. T. K. C. and N. M. are visiting scientists from the Indian Institute of Chemical Technology, Hyderabad, and Meiji Seika Kaisha, Ltd., Japan, respectively.

Received, 15th January 1993; Com. 3/00255A

References

- 1 A. D. Piscopio, N. Minowa, T. K. Chakraborty, K. Koide and P. Bertinato and K. C. Nicolaou, preceding communication.
- 2 Isolation: (a) C. Vézina, A. Kudelski and S. N. Sehgal, *J. Antibiot.*, 1975, **28**, 721; (b) S. N. Sehgal, H. Baker and C. Vézina, *J. Antibiot.*, 1975, **28**, 727; Structure: (c) D. C. N. Swindells, P. S. White and J. A. Findlay, *Can. J. Chem.*, 1978, **56**, 2491; (d) J. A. Findlay and L. Radics, *Can. J. Chem.*, 1980, **58**, 579; Synthetic studies: (e) M. J. Fisher, C. D. Myers, J. Joglar,



Scheme 5 Synthesis of key intermediate **2**. *Reagents and conditions:* (a) **3** (1.0 equiv.), **4** (2.5 equiv.), CrCl₂ (containing 0.1% NiCl₂) (10 equiv.), DMSO, 25 °C, 12 h, 87% (based on 10% recovered aldehyde); (b) TIPSOTf (1.5 equiv.), 2,6-lutidine (3 equiv.), CH₂Cl₂, 0 °C, 15 min., 98%; (c) HF-pyridine, THF, 25 °C, 3 h, 97%; (d) (COCl)₂ (1.5 equiv.), DMSO (3.2 equiv.), Et₃N (5 equiv.), CH₂Cl₂, -78 to -10 °C, 1 h, 96%; (e) **5** (2.0 equiv.), Bu₃BOTf (2.3 equiv.), Et₃N (2.6 equiv.), CH₂Cl₂, -78 to 0 °C, 1 h then **24** (1 equiv.), -78 to 25 °C, 3 h, 95%; (f) LiBH₄ (2.2 equiv.), H₂O (2.2 equiv.), Et₂O, 0 °C, 1 h, 98%; (g) TsCl (2 equiv.), Et₃N (4 equiv.), DMAP (0.2 equiv.), CH₂Cl₂, 25 °C, 24 h, 90% (based on 10% recovered diol); (h) LiEt₃BH (10 equiv.), THF, 0 °C, 2 h, 91%; (i) *N*-Boc-L-pipecolic acid (**6**) (5 equiv.), diisopropylcarbodiimide (5 equiv.), diisopropylethylamine (1 equiv.), 4-pyrrolidinopyridine (0.5 equiv.), CH₂Cl₂, 0 °C, 4 h, 85%; (j) OsO₄ (0.2 equiv.), *N*-methylmorpholine *N*-oxide (3.5 equiv.), acetone-H₂O (2:1), 25 °C, 12 h; (k) Pb(OAc)₄ (2.4 equiv.), Na₂CO₃ (3 equiv.), C₆H₆, 0 to 25 °C, 15 min., 75% from olefin; (l) CHI₃ (4 equiv.), CrCl₂ (12 equiv.), THF-dioxane (4:1), 25 °C, 1 h, 94%; (m) DDQ (3 equiv.), CHCl₃-H₂O (19:1), 25 °C, 1 h, 98%; (n) TESOTf (15 equiv.), 2,6-lutidine (20 equiv.), CH₂Cl₂, 0 °C, 1 h then silica gel, CH₂Cl₂, 25 °C, 6 h, 94%.

DMAP = 4-dimethylaminopyridine; DDQ = 2,3-dichloro-5,6-dicyano-1,4-benzoquinone.

- S.-H. Chen and S. J. Danishefsky, *J. Org. Chem.*, 1991, **56**, 5826; (f) S.-H. Chen, R. F. Horvath, J. Joglar, M. J. Fisher and S. J. Danishefsky, *J. Org. Chem.*, 1991, **56**, 5834; (g) S. D. Meyer, T. Miwa, M. Nakatsuka and S. L. Schreiber, *J. Org. Chem.*, 1992, **57**, 5058; (h) D. Romo, D. D. Johnson, L. Plamondon, T. Miwa and S. L. Schreiber, *J. Org. Chem.*, 1992, **57**, 5060; (i) M. R. Hale and A. H. Hoveyda, *J. Org. Chem.*, 1992, **57**, 1643.
- 3 D. A. Evans, D. J. Mathre and W. L. Scott, *J. Org. Chem.*, 1985, **50**, 1830; D. A. Evans, R. P. Polniaszek, K. M. DeVries, D. E. Guinn and D. J. Mathre, *J. Am. Chem. Soc.*, 1991, **113**, 7613.

- 4 T. P. Penning, S. W. Djuric, R. A. Haack, V. J. Kalish, J. M. Miyashiro, B. W. Rowell and S. S. Yu, *Synth. Commun.*, 1990, **20**, 307.
 - 5 M. Nakatsuka, J. A. Ragan, T. Sammakia, D. B. Smith, D. E. Vehling and S. L. Schreiber, *J. Am. Chem. Soc.*, 1990, **112**, 5583.
 - 6 H. C. Brown and K. S. Bhat, *J. Am. Chem. Soc.*, 1986, **108**, 5919.
 - 7 E. J. Corey and P. L. Fuchs, *Tetrahedron Lett.*, 1972, 3769.
 - 8 D. W. Hart, T. F. Blackburn and J. Schwartz, *J. Am. Chem. Soc.*, 1975, **97**, 679.
 - 9 I. Minami, K. Takahashi, I. Shimizu, T. Kimura and J. Tsuji, *Tetrahedron*, 1986, **42**, 2971.
 - 10 J. L. Luche, *J. Am. Chem. Soc.*, 1978, **100**, 2226.
 - 11 A. E. Wick, D. Felix, K. Steen and A. Eschenmoser, *Helv. Chim. Acta*, 1964, **47**, 2425.
 - 12 M. A. Blenchette, W. Choy, J. T. Davis, A. P. Esserfeld, S. Masamune, W. P. Roush and T. Sakai, *Tetrahedron Lett.*, 1984, **25**, 2183.
 - 13 I. Ojima and T. Kogure, *Organometallics*, 1982, **1**, 1390.
 - 14 K. Takai, K. Kimura, T. Kuroda, T. Hiyama and H. Nozaki, *Tetrahedron Lett.*, 1983, **24**, 5281; H. Jin, J. Werniski, W. J. Christ and Y. Kishi, *J. Am. Chem. Soc.*, 1986, **108**, 5644; P. Cintas, *Synthesis*, 1992, 248.
 - 15 K. Takai, M. Tagashira, T. Kurode, K. Oshima, K. Utimoto and H. Nozaki, *J. Am. Chem. Soc.*, 1986, **108**, 6048.
-